{"date":"2025-12-24","count":21,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4166-2025-12-24-2204-w1xse4","company_id":"4166","company":"友霖","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"22:04:11","subject":"本公司Tofacitinib向美國FDA提交挑戰專利學名藥(Paragraph IV)藥證申請(ANDA)獲完全回應信函(Complete Response Letter, CRL)通知","clause":"第10款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：友霖（4166），2025-12-24 22:04，「本公司Tofacitinib向美國FDA提交挑戰專利學名藥(Paragraph IV)藥證申請(ANDA)獲完全回應信函」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-12-24-1814-11vxjjv","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"18:14:35","subject":"本公司114年現金增資股款催繳公告","clause":"第51款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-12-24 18:14，「本公司114年現金增資股款催繳公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6949-2025-12-24-1814-19q8zho","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"18:14:11","subject":"公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜","clause":"第45款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2025-12-24 18:14，「公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4198-2025-12-24-1808-1a80d02","company_id":"4198","company":"欣大健康","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"18:08:33","subject":"本公司受邀參加中國信託證券舉辦之線上法人說明會","clause":"第12款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：欣大健康（4198），2025-12-24 18:08，「本公司受邀參加中國信託證券舉辦之線上法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2025-12-24-1803-1pwsttl","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"18:03:44","subject":"公告本公司自主開發的Tucidinostat鹽類新藥GNTbm-CC-02，經審查取得韓國發明專利","clause":"第44款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2025-12-24 18:03，「公告本公司自主開發的Tucidinostat鹽類新藥GNTbm-CC-02，經審查取得韓國發明專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4747-2025-12-24-1754-ub84r7","company_id":"4747","company":"強生*","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"17:54:31","subject":"公告本公司114年第一次股東臨時會重要決議事項","clause":"第18款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：強生*（4747），2025-12-24 17:54，「公告本公司114年第一次股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6576-2025-12-24-1752-4w2m4m","company_id":"6576","company":"逸達","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"17:52:10","subject":"本公司新劑型新藥FP-001 42 mg用於治療兒童中樞性性早熟三期臨床試驗達到主要療效指標","clause":"第10款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：逸達（6576），2025-12-24 17:52，「本公司新劑型新藥FP-001 42 mg用於治療兒童中樞性性早熟三期臨床試驗達到主要療效指標」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6547-2025-12-24-1728-2lkq9k","company_id":"6547","company":"高端疫苗","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"17:28:01","subject":"公告本公司114年股東臨時會重要決議事項","clause":"第18款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：高端疫苗（6547），2025-12-24 17:28，「公告本公司114年股東臨時會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6936-2025-12-24-1725-5j9o7v","company_id":"6936","company":"永鴻生技","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"17:25:35","subject":"公告本公司受邀參加凱基證券舉辦之法人說明會","clause":"第12款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：永鴻生技（6936），2025-12-24 17:25，「公告本公司受邀參加凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7850-2025-12-24-1722-10jca0t","company_id":"7850","company":"寶泰生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"17:22:53","subject":"本公司受邀參加凱基證券舉辦之法人說明會","clause":"第30款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：寶泰生醫（7850），2025-12-24 17:22，「本公司受邀參加凱基證券舉辦之法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6919-2025-12-24-1713-1uxst28","company_id":"6919","company":"康霈*","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"17:13:03","subject":"本公司新藥CBL-514注射劑合併tirzepatide (Eli Lilly)用於體重管理之二期臨床試驗(CBL-0201WR)申請，今日已完成美國FDA IND送件","clause":"第10款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：康霈*（6919），2025-12-24 17:13，「本公司新藥CBL-514注射劑合併tirzepatide (Eli Lilly)用於體重管理之二期臨床試驗(CBL-02」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6864-2025-12-24-1703-19q8zho","company_id":"6864","company":"元樟生技","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"17:03:00","subject":"公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜","clause":"第37款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：元樟生技（6864），2025-12-24 17:03，「公告本公司114年度現金增資全體董事放棄認購股數達得認購股數二分之一以上，並洽特定人認購事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-8279-2025-12-24-1641-1x234cv","company_id":"8279","company":"生展","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"16:41:52","subject":"本公司受邀參加群益金鼎證券舉辦之線上法說會。","clause":"第12款","fact_date":"2025-12-26","cite_as":"公開資訊觀測站重大訊息：生展（8279），2025-12-24 16:41，「本公司受邀參加群益金鼎證券舉辦之線上法說會。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6665-2025-12-24-1633-jz92gs","company_id":"6665","company":"康聯生醫","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"16:33:10","subject":"公告本公司董事會決議通過擬購置不動產案","clause":"第17款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：康聯生醫（6665），2025-12-24 16:33，「公告本公司董事會決議通過擬購置不動產案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2025-12-24-1555-1rphmbj","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2025-12-24","time":"15:55:54","subject":"本公司受邀參加元富證券法人說明會","clause":"第12款","fact_date":"2025-12-29","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2025-12-24 15:55，「本公司受邀參加元富證券法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6939-2025-12-24-1530-1m4y99v","company_id":"6939","company":"啟弘生技","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"15:30:41","subject":"更正-公告本公司董事會決議員工認股權憑證轉換普通股增資基準日","clause":"第9款","fact_date":"2025-12-15","cite_as":"公開資訊觀測站重大訊息：啟弘生技（6939），2025-12-24 15:30，「更正-公告本公司董事會決議員工認股權憑證轉換普通股增資基準日」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4178-2025-12-24-1524-hqbh","company_id":"4178","company":"永笙-KY","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"15:24:21","subject":"代重要子公司台灣永生公告新任業務副總","clause":"第11款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：永笙-KY（4178），2025-12-24 15:24，「代重要子公司台灣永生公告新任業務副總」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6539-2025-12-24-1504-1xkzaqq","company_id":"6539","company":"麗彤","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"15:04:38","subject":"代重要子公司GOODEAL ENTERPRISES LIMITED公告辦理現金減資案","clause":"第9款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：麗彤（6539），2025-12-24 15:04，「代重要子公司GOODEAL ENTERPRISES LIMITED公告辦理現金減資案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4172-2025-12-24-1503-1qb6ki2","company_id":"4172","company":"因華","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"15:03:49","subject":"公告本公司董事會決議擬向金管會申請114年現金增資發行新股計畫變更案","clause":"第9款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：因華（4172），2025-12-24 15:03，「公告本公司董事會決議擬向金管會申請114年現金增資發行新股計畫變更案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4117-2025-12-24-1455-isqttc","company_id":"4117","company":"普生","market":"興櫃","industry":"生技醫療","date":"2025-12-24","time":"14:55:35","subject":"公告本公司董事會重要決議事項","clause":"第44款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：普生（4117），2025-12-24 14:55，「公告本公司董事會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6796-2025-12-24-1342-1hp6h2f","company_id":"6796","company":"晉弘","market":"上市","industry":"生技醫療","date":"2025-12-24","time":"13:42:18","subject":"本公司拋棄式關節鏡EJA 100通過美國食品藥物管理局(FDA)510(k)審查","clause":"第51款","fact_date":"2025-12-24","cite_as":"公開資訊觀測站重大訊息：晉弘（6796），2025-12-24 13:42，「本公司拋棄式關節鏡EJA 100通過美國食品藥物管理局(FDA)510(k)審查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}